UNSPSC 51332820: Perazine

This classification denotes a dopamine antagonist with the molecular formula C20H25N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8915147A2B, chemically known as 10h-phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)- but generally known as perazine, which bears US NIH Compound Identifier 4744. European Medicines Agency schedules Perazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14811MIG.

World Health Organization schedules perazine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PERAZINE remains the US FDA Preferred Term for this commodity. Perazine bears US NLM identifiers UMLS ID C0030969 and NCI Concept Code C81093. SMILES: S1C2C(N(CCCN3CCN(CC3)C)C3C1CCCC3)CCCC2.

UNSPSC 51332820 Perazine is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, including both branded and generic medications, over-the-counter products, and opioid-response medications such as naloxone. State and local purchasing under this code reflects broader healthcare supply-chain activity: county health departments, state health and human services agencies, and multistate cooperative purchasing alliances solicit pharmaceutical products through RFPs, RFQs, and IBFs to support community health initiatives, employee benefit programs, and emergency-response capacity. The scope includes negotiation of pricing models with manufacturers and wholesalers, compliance with cGMP and Drug Supply Chain Security Act (DSCSA) requirements, and management of quarterly or ongoing deliveries to multiple facilities.

Recent activity spans Florida, Texas, and Minnesota, with multistate cooperative arrangements extending across participating jurisdictions including Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026, due July 26, 2023, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 with response due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, requiring vendors to work through three authorized wholesalers and demonstrating pricing flexibility through flat-price, net-price, or WAC-minus models.